A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Methods
2.2.1. Preparation of DES with BA Physical Mixture
2.2.2. Preparation of Amorphous DES and Co-Amorphous DES–BA
2.2.3. Preparation of Desloratadine Polymorph Form II
2.2.4. Preparation of Desloratadine-Benzoic Acid Salt
2.2.5. Solid-State Characterization of Co-Amorphous Desloratadine-Benzoic Acid
Powder X-ray Diffraction
Differential Scanning Calorimetry
Fourier Transform Infrared Spectroscopy
Polarized Light Microscopy
2.2.6. Physical Stability
2.2.7. Solubility
2.2.8. Dissolution
3. Results and Discussion
3.1. Making of Amorphous DES and Co-Amorphous DES–BA
3.2. Characterization of Co-Amorphous DES–BA
3.2.1. X-ray Powder Diffraction Study
3.2.2. Differential Scanning Calorimetry
3.2.3. Fourier Transform Infrared Spectroscopy
3.2.4. Polarized Light Microscopy (PLM)
3.3. Physical Stability of Co-Amorphous
3.4. Making of DES–BA Co-Amorphous Salt
3.5. Solubility of DES Crystal and Co-Amorphous DES–BA
3.6. Dissolution of DES Crystal and Co-Amorphous DES–BA
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Lu, J.; Rohani, S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs). Curr. Med. Chem. 2009, 16, 884–905. [Google Scholar] [CrossRef] [PubMed]
- Blagden, N.; de Matas, M.; Gavan, P.T.; York, P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 2007, 59, 617–630. [Google Scholar] [CrossRef] [PubMed]
- Bhugra, C.; Shmeis, R.; Pikal, M.J. Role of Mechanical Stress in Crystallization and Relaxation Behavior of Amorphous Indomethacin. J. Pharm. Sci. 2008, 97, 4446–4458. [Google Scholar] [CrossRef] [PubMed]
- Yoshioka, M.; Hancock, B.C.; Zografi, G. Crystallization of Indomethacin from the Amorphous State below and above Its Glass Transition Temperature. J. Pharm. Sci. 1994, 83, 1700–1705. [Google Scholar] [CrossRef] [PubMed]
- Hancock, B.C.; Zografi, G. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. J. Pharm. Sci. 1997, 86, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Yu, L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 2001, 48, 27–42. [Google Scholar] [CrossRef]
- Zhang, G.G.Z.; Law, D.; Schmitt, E.A.; Qiu, Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug Deliv. Rev. 2004, 56, 371–390. [Google Scholar] [CrossRef] [PubMed]
- Janssens, S.; Van den Mooter, G. Review: Physical chemistry of solid dispersions. J. Pharm. Pharmacol. 2009, 61, 1571–1586. [Google Scholar] [CrossRef] [PubMed]
- Vasconcelos, T.; Sarmento, B.; Costa, P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12, 1068–1075. [Google Scholar] [CrossRef] [PubMed]
- Hancock, B.C.; Shamblin, S.L.; Zografi, G. Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures. Pharm. Res. 1995, 12, 799–806. [Google Scholar] [CrossRef] [PubMed]
- Maniruzzaman, M.; Morgan, D.J.; Mendham, A.P.; Pang, J.; Snowden, M.J.; Douroumis, D. Drug–polymer intermolecular interactions in hot-melt extruded solid dispersions. Int. J. Pharm. 2013, 443, 199–208. [Google Scholar] [CrossRef] [PubMed]
- He, Y.; Ho, C. Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development. J. Pharm. Sci. 2015, 104, 3237–3258. [Google Scholar] [CrossRef] [PubMed]
- Rumondor, A.C.F.; Taylor, L.S. Effect of Polymer Hygroscopicity on the Phase Behavior of Amorphous Solid Dispersions in the Presence of Moisture. Mol. Pharm. 2010, 7, 477–490. [Google Scholar] [CrossRef] [PubMed]
- Laitinen, R.; Löbmann, K.; Strachan, C.J.; Grohganz, H.; Rades, T. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 2013, 453, 65–79. [Google Scholar] [CrossRef] [PubMed]
- Shrivastava, A.; Ursekar, B.; Kapadia, C. Design, Optimization, Preparation and Evaluation of Dispersion Granules of Valsartan and Formulation into Tablets. Curr. Drug Deliv. 2009, 6, 28–37. [Google Scholar] [CrossRef] [PubMed]
- Serajuddin, A.T.M. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88, 1058–1066. [Google Scholar] [CrossRef] [PubMed]
- Guo, Y.; Shalaev, E.; Smith, S. Physical stability of pharmaceutical formulations: Solid-state characterization of amorphous dispersions. TrAC Trends Anal. Chem. 2013, 49, 137–144. [Google Scholar] [CrossRef]
- Dengale, S.J.; Grohganz, H.; Rades, T.; Löbmann, K. Recent advances in co-amorphous drug formulations. Adv. Drug Deliv. Rev. 2016, 100, 116–125. [Google Scholar] [CrossRef] [PubMed]
- Chavan, R.B.; Thipparaboina, R.; Kumar, D.; Shastri, N.R. Co amorphous systems: A product development perspective. Int. J. Pharm. 2016, 515, 403–415. [Google Scholar] [CrossRef] [PubMed]
- Chieng, N.; Aaltonen, J.; Saville, D.; Rades, T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur. J. Pharm. Biopharm. 2009, 71, 47–54. [Google Scholar] [CrossRef] [PubMed]
- Suresh, K.; Mannava, M.K.C.; Nangia, A. A novel curcumin–artemisinin coamorphous solid: Physical properties and pharmacokinetic profile. RSC Adv. 2014, 4, 58357–58361. [Google Scholar] [CrossRef]
- Grohganz, H.; Löbmann, K.; Priemel, P.; Tarp Jensen, K.; Graeser, K.; Strachan, C.; Rades, T. Amorphous drugs and dosage forms. J. Drug Deliv. Sci. Technol. 2013, 23, 403–408. [Google Scholar] [CrossRef]
- Allesø, M.; Chieng, N.; Rehder, S.; Rantanen, J.; Rades, T.; Aaltonen, J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen–cimetidine mixtures prepared by mechanical activation. J. Control. Release 2009, 136, 45–53. [Google Scholar] [CrossRef] [PubMed]
- Ali, A.M.A.; Ali, A.A.; Maghrabi, I.A. Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation. Acta Pharm. 2015, 65, 133–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gao, Y.; Liao, J.; Qi, X.; Zhang, J. Coamorphous repaglinide–saccharin with enhanced dissolution. Int. J. Pharm. 2013, 450, 290–295. [Google Scholar] [CrossRef] [PubMed]
- Löbmann, K.; Grohganz, H.; Laitinen, R.; Strachan, C.; Rades, T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs—Part 1: Preparation, stability and dissolution enhancement. Eur. J. Pharm. Biopharm. 2013, 85, 873–881. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Aaltonen, J.; Tian, F.; Saville, D.J.; Rades, T. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Eur. J. Pharm. Biopharm. 2009, 71, 64–70. [Google Scholar] [CrossRef] [PubMed]
- Vasconcelos, T.; Marques, S.; das Neves, J.; Sarmento, B. Amorphous solid dispersions: Rational selection of a manufacturing process. Adv. Drug Deliv. Rev. 2016, 100, 85–101. [Google Scholar] [CrossRef] [PubMed]
- Popović, G.; Čakar, M.; Agbaba, D. Acid-base equilibria and solubility of loratadine and desloratadine in water and micellar media. J. Pharm. Biomed. Anal. 2009, 49, 42–47. [Google Scholar] [CrossRef] [PubMed]
- DuBuske, L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin. Pharmacother. 2005, 6, 2511–2523. [Google Scholar] [CrossRef] [PubMed]
- Ali, S.M.; Upadhyay, S.K.; Maheshwari, A. NMR spectroscopic study of the inclusion complex of desloratadine with β-cyclodextrin in solution. J. Incl. Phenom. Macrocycl. Chem. 2007, 59, 351–355. [Google Scholar] [CrossRef]
- Ray, A.K.; Patel, H.; Patel, M.R. Salt and Polymorphs of Desloratadine Hemifumarate. U.S. Patent 6,962,924 B2, 11 August 2005. [Google Scholar]
- Kolašinac, N.; Kachrimanis, K.; Djuriš, J.; Homšek, I.; Grujić, B.; Ibrić, S. Spray coating as a powerful technique in preparation of solid dispersions with enhanced desloratadine dissolution rate. Drug Dev. Ind. Pharm. 2013, 39, 1020–1027. [Google Scholar] [CrossRef] [PubMed]
- Kolašinac, N.; Kachrimanis, K.; Homšek, I.; Grujić, B.; Ðurić, Z.; Ibrić, S. Solubility enhancement of desloratadine by solid dispersion in poloxamers. Int. J. Pharm. 2012, 436, 161–170. [Google Scholar] [CrossRef] [PubMed]
- Ainurofiq, A.; Mauludin, R.; Mudhakir, D.; Soewandhi, S.N. Synthesis, characterization, and stability study of desloratadine multicomponent crystal formation. Res. Pharm. Sci. 2018, 13, 93–102. [Google Scholar] [CrossRef] [PubMed]
- Ainurofiq, A.; Mauludin, R.; Mudhakir, D.; Umeda, D.; Soewandhi, S.N.; Putra, O.D.; Yonemochi, E. Improving mechanical properties of desloratadine via multicomponent crystal formation. Eur. J. Pharm. Sci. 2018, 111, 65–72. [Google Scholar] [CrossRef] [PubMed]
- Lim, A.W.; Löbmann, K.; Grohganz, H.; Rades, T.; Chieng, N. Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling. J. Pharm. Pharmacol. 2016, 68, 36–45. [Google Scholar] [CrossRef] [PubMed]
- Graeser, K.; Patterson, J.; Rades, T. Applying Thermodynamic and Kinetic Parameters to Predict the Physical Stability of Two Differently Prepared Amorphous Forms of Simvastatin. Curr. Drug Deliv. 2009, 6, 374–382. [Google Scholar] [CrossRef] [PubMed]
- Jensen, K.T.; Löbmann, K.; Rades, T.; Grohganz, H. Improving Co-Amorphous Drug Formulations by the Addition of the Highly Water Soluble Amino Acid, Proline. Pharmaceutics 2014, 6, 416–435. [Google Scholar] [CrossRef] [PubMed]
- Löbmann, K.; Strachan, C.; Grohganz, H.; Rades, T.; Korhonen, O.; Laitinen, R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur. J. Pharm. Biopharm. 2012, 81, 159–169. [Google Scholar] [CrossRef] [PubMed]
- Trasi, N.S.; Byrn, S.R. Mechanically Induced Amorphization of Drugs: A Study of the Thermal Behavior of Cryomilled Compounds. AAPS PharmSciTech 2012, 13, 772–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heinz, A.; Gordon, K.C.; McGoverin, C.M.; Rades, T.; Strachan, C.J. Understanding the solid-state forms of fenofibrate–A spectroscopic and computational study. Eur. J. Pharm. Biopharm. 2009, 71, 100–108. [Google Scholar] [CrossRef] [PubMed]
- Qian, S.; Heng, W.; Wei, Y.; Zhang, J.; Gao, Y. Coamorphous Lurasidone Hydrochloride–Saccharin with Charge-Assisted Hydrogen Bonding Interaction Shows Improved Physical Stability and Enhanced Dissolution with pH-Independent Solubility Behavior. Cryst. Growth Des. 2015, 15, 2920–2928. [Google Scholar] [CrossRef]
- Costa, P.; Sousa Lobo, J.M. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13, 123–133. [Google Scholar] [CrossRef]
Compound | Solubility (Mole) in | |
---|---|---|
Water | HCl 0.1 N | |
DES | 1.03 × 10−3 ± 3.22 × 10−5 | 1.16 × 10−1 ± 2.25 × 10−4 |
Co-amorphous DES–BA | 1.97 × 10−2 ± 6.01 × 10−4 | 2.55 × 10−1 ± 2.52 × 10−3 |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ainurofiq, A.; Mauludin, R.; Mudhakir, D.; Soewandhi, S.N. A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation. Pharmaceutics 2018, 10, 85. https://doi.org/10.3390/pharmaceutics10030085
Ainurofiq A, Mauludin R, Mudhakir D, Soewandhi SN. A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation. Pharmaceutics. 2018; 10(3):85. https://doi.org/10.3390/pharmaceutics10030085
Chicago/Turabian StyleAinurofiq, Ahmad, Rachmat Mauludin, Diky Mudhakir, and Sundani Nurono Soewandhi. 2018. "A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation" Pharmaceutics 10, no. 3: 85. https://doi.org/10.3390/pharmaceutics10030085
APA StyleAinurofiq, A., Mauludin, R., Mudhakir, D., & Soewandhi, S. N. (2018). A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation. Pharmaceutics, 10(3), 85. https://doi.org/10.3390/pharmaceutics10030085